Biblio
“A Continuous Extension of Gene Set Enrichment Analysis Using the Likelihood Ratio Test Statistics Identifies Vascular Endothelial Growth Factor as a Candidate Pathway for Alzheimer's Disease via ITGA5.”, J Alzheimers Dis, vol. 97, no. 2, pp. 635-648, 2024.
, “Interaction Between Arteriosclerosis and Amyloid-β on Cognitive Function.”, J Alzheimers Dis, vol. 97, no. 2, pp. 953-961, 2024.
, “Association of Interleukin-6 and Interleukin-8 with Cognitive Decline in an Asian Memory Clinic Population.”, J Alzheimers Dis, vol. 92, no. 2, pp. 445-455, 2023.
, “Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer's Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer's Disease Continuum.”, J Alzheimers Dis, vol. 92, no. 4, pp. 1385-1397, 2023.
, “Chiral Amino Acid Profiling in Serum Reveals Potential Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. 1, pp. 291-301, 2023.
, “Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 1, pp. 95-107, 2023.
, “From Association to Intervention: The Alzheimer's Disease-Associated Processes and Targets (ADAPT) Ontology.”, J Alzheimers Dis, vol. 94, no. s1, pp. S87-S96, 2023.
, “Neuroinflammation: A Common Pathway in Alzheimer's Disease and Epilepsy.”, J Alzheimers Dis, vol. 94, no. s1, pp. S253-S265, 2023.
, “Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 615-628, 2023.
, “Plasma Soluble ST2 Levels Are Higher in Neurodegenerative Disorders and Associated with Poorer Cognition.”, J Alzheimers Dis, vol. 92, no. 2, pp. 573-580, 2023.
, “Soluble TREM2, Alzheimer's Disease Pathology, and Risk for Progression of Cerebral Small Vessel Disease: A Longitudinal Study.”, J Alzheimers Dis, vol. 92, no. 1, pp. 311-322, 2023.
, “Understanding the Involvement of microRNAs in Mitochondrial Dysfunction and Their Role as Potential Biomarkers and Therapeutic Targets in Parkinson's Disease.”, J Alzheimers Dis, vol. 94, no. s1, pp. S187-S202, 2023.
, “5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 573-585, 2022.
, “Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1267-1282, 2022.
, “A Blood Test for Alzheimer's Disease: It's about Time or Not Ready for Prime Time?”, J Alzheimers Dis, vol. 90, no. 3, pp. 963-966, 2022.
, “Blood Tests for Alzheimer's Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance.”, J Alzheimers Dis, vol. 90, no. 3, pp. 967-974, 2022.
, “Functional Neurophysiological Biomarkers of Early-Stage Alzheimer's Disease: A Perspective of Network Hyperexcitability in Disease Progression.”, J Alzheimers Dis, vol. 88, no. 3, pp. 809-836, 2022.
, “Rheumatoid Arthritis, Cognitive Impairment, and Neuroimaging Biomarkers: Results from the Mayo Clinic Study of Aging.”, J Alzheimers Dis, vol. 89, no. 3, pp. 943-954, 2022.
, “Shortening of Saccades as a Possible Easy-to-Use Biomarker to Detect Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 88, no. 2, pp. 609-618, 2022.
, “A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 485-501, 2022.
, “APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 79, no. 2, pp. 511-530, 2021.
, “Could Altered Evoked Pain Responsiveness Be a Phenotypic Biomarker for Alzheimer's Disease Risk? A Cross-Sectional Analysis of Cognitively Healthy Individuals.”, J Alzheimers Dis, vol. 79, no. 3, pp. 1227-1233, 2021.
, “Dementia and COVID-19, a Bidirectional Liaison: Risk Factors, Biomarkers, and Optimal Health Care.”, J Alzheimers Dis, vol. 82, no. 3, pp. 883-898, 2021.
, “Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 81, no. 2, pp. 629-640, 2021.
, “Is the Frontal Lobe the Primary Target of SARS-CoV-2?”, J Alzheimers Dis, vol. 81, no. 1, pp. 75-81, 2021.
,